Leo Lin

Leo Lin

Auto-generated profile, based on publicly available information

Leo Lin

Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2018 in Cancers
Verified
Journal Article
Open access
PDF file
ZSZachary Schrank
Zachary Schrank
GCGagan Chhabra
Gagan Chhabra
LLLeo Lin
Leo Lin
TITsatsral Iderzorig
Tsatsral Iderzorig
COChike Osude
Chike Osude
NPNeelu Puri
Neelu Puri
Lung cancer is treated with many conventional therapies, such as surgery, radiation, and chemotherapy. However, these therapies have multiple undesirable side effects. To bypass the side effects elicited by these conventional treatments, molecularly-targeted therapies are currently in use or under development. Current molecularly-targeted therapies effectively target specific biomarkers, which are commonly overexpressed in lung cancers and can cause increased tumorigenicity. Unfortunately, several molecularly-targeted therapies are associated with initial dramatic responses followed by acquired resistance due to spontaneous mutations or activation of signaling pathways. Acquired resistance to molecularly targeted therapies presents a major clinical challenge in the treatment of lung cancer. Therefore, to address this clinical challenge and to improve lung cancer patient prognosis, we need to understand the mechanism of acquired resistance to current therapies and develop additional novel therapies. This review concentrates on various lung cancer biomarkers, including EGFR, ALK, and BRAF, as well as their potential mechanisms of drug resistance.